Based on the mechanisms described above, inhibition of IDO enzymatic activity during cancer therapy is desirable to restore immune reactivity against tumors and to prevent the re-establishment of immune suppression following the active immunization processes that are triggered by tumor vaccination, chemotherapy, radiotherapy, or checkpoint inhibitor therapy. Here, IDO1 is linked to neoplasm.